Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S reports a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,221,620 Genmab shares, equal to 5.01% of the company’s share capital and voting rights as of March 31, 2026.
The filing reflects a small increase from a prior 4.99% position and confirms that the holding is via shares only, with no additional voting exposure through financial instruments.
Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.
Genmab A/S reports changes to its board leadership and new employee equity incentives. Following the Annual General Meeting, Deirdre P. Connelly was appointed Chair of the Board and Pernille Erenbjerg was appointed Deputy Chair.
The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees of Genmab and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the closing share price of DKK 1,645.00 at grant, and vests after three years subject to program conditions. Each warrant is also granted cost-free with an exercise price of DKK 1,645.00, has a fair value of DKK 530.62 based on the Black-Scholes formula, vests after three years, and expires seven years from the grant date.
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.
Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.
From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S filed a Form 6-K to share a company announcement correcting the reported price for recent insider equity awards. A prior notice had shown a share price of DKK 0.00 for transactions involving managerial employees and related persons; the correct price is DKK 1,867.50 per share.
The correction covers acquisitions of Genmab shares due to vesting of restricted stock units granted on February 24, 2023 to President & CEO Jan van de Winkel, EVP & CFO Anthony Pagano, and board members Mijke Zachariasse, Martin Schultz, and Michael Kavanagh. All transactions occurred outside the market and reflect routine equity compensation vesting rather than open-market trading.